FDA
-
-
-
-
-
-
-
United Therapeutics' Tyvaso meets primary endpoint in IPF study
-
-
-
-
-
-
-
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
-
-
-
-
-
-
-
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically
-
-
-
-
-
-
-
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
-
-
-
-
-
-
-
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
-
-
-
-
-
-
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)
-
328,513 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

